Brincidofovir-d6

Brincidofovir-d6 (CMX001-d6) is the deuterium labeled Brincidofovir (HY-14532) . Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.[1][2][3][4].

Product Specifications

CAS Number

[1917374-64-1]

Product Name Alternative

CMX001-d6; HDP-CDV-d6

UNSPSC

12352005

Target

CMV; HSV; Isotope-Labeled Compounds; Orthopoxvirus

Related Pathways

Anti-infection; Others

Field of Research

Infection

Smiles

NC1=NC(N(C[C@@H](CO)OCP(O)(OC([2H])([2H])C([2H])([2H])C([2H])([2H])OCCCCCCCCCCCCCCCC)=O)C=C1)=O

Molecular Formula

C27H46D6N3O7P

Molecular Weight

567.73

References & Citations

[1]Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9 (11) :320.|[2]Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129 (14) :2033-2037.|[3]Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40 (6) :e364-e368.|[4]Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89 (6) :3295-3307.